The prognosis for chronic inflammatory demyelinating polyneuropathy varies from patient to patient, depending primarily on how early the condition is diagnosed and how well treatment works, according to the GIBS/CIPD Foundation International. Patients require lifelong care and may need special accommodations at home. Without treatment, about a third of patients diagnosed with CIPD become wheelchair dependent.Continue Reading
Because symptoms of CIPD occur gradually over months or years, it may not be diagnosed until the patient has suffered significant nerve damage, the GIBS/CIPD Foundation International explains. Depending of the nerve damage's severity, response to treatment may be delayed or limited. Prompt treatment can greatly affect quality of life and can even cure the disease in some patients.
CIPD treatment typically involves a variety of medications, including corticosteroids, often used as an initial treatment, the GIBS/CIPD Foundation International reports. The only medication FDA-approved specifically for CIPD, high-dose intravenous immune globulins, consists of antibodies from donors. Patients sometimes undergo plasma exchange or plasmapheresis to remove harmful antibodies from the blood.
Most cases of CIPD involve a progressive symmetrical motor and sensory neuropathy that affects proximal and distal muscles with loss of deep tendon reflexes, the GIBS/CIPD Foundation states. Variants of CIPD may be asymmetric or affect solely motor or sensory function.Learn more about Conditions & Diseases